Amprion Patent Information

Amprion continues to build its Intellectual Property surrounding the company's proprietary methodology for highly sensitive detection of misfolded proteins and amyloid-like aggregates. Recently, fundamental patents have issued in key geographies which expand our extensive coverage in the EU and UK. The issued patents apply broadly to the methodology known alternatively as Seed Amplification Assay (SAA), Protein Misfolding Cyclic Amplification (PMCA) or Real Time Quaking induced Conversion (RT-QuiC).

Amprion’s owned or exclusively-licensed alpha-synuclein portfolio is particularly extensive. The portfolio currently includes multiple allowed and/or issued patents in the United States, EU, Japan, UK, Korea, Singapore, Australia, Israel, Canada, and Mexico, with applications pending in India, China, Hong Kong, and Brazil. Amprion also has an issued US patent and pending applications worldwide directed to Amprion’s proprietary alpha-synuclein SAA substrate plus other key components needed for robust, reliable and reproducible performance of the technology.”

Download Spec Sheet

SYNTap Biomarker Test performance characteristics.


FDA Breakthrough

The U.S. FDA awarded Amprion Breakthrough Device Designation. 

Amprion Science

We help accelerate personalized medicine through biomarker testing.

Russ walking through Amprion Lab

Molecule Testing Leads to Personalized Medicine

~ CEO, Russ Lebovitz, M.D./Ph.D

Neurodegenerative diseases affect individuals differently. For instance, ten patients can have ten different biomarker profiles. In addition, symptoms often overlap, leading to diagnostic challenges.

The SYNTap Test offers physicians a molecular tool to greatly improve diagnosis accuracy. Our goal is to develop personalized medicine through biomarker testing.


Amprion has some important news we need to share with you!

To improve patient access to the SYNTap® biomarker test (CSF), Amprion is reducing the self-pay price for tests with service dates on or after July 1, 2023.

Old self-pay price: $1500.00. New self-pay price: $995.00

Effective July 1, 2023, there is a New ABN (Advanced Beneficiary Notification) form for use when ordering the SYNTap® biomarker test (CSF) for patients on Medicare. Order Process

CPT/PLA – The SYNTap® test has been issued a dedicated PLA code to be used when billing: 0393U
We have applied to be a medicare provider and will soon be able to courtesy bill Medicare for your patients.